VA-lip HSP47 eye drops resolve established lacrimal gland fibrosis in chronic GVHD. Mice were transplanted as in Figure 1. A group of allogeneic recipients (Allo) was treated with VA-lip HSP47 eye drops or VA-lip Scr eye drops daily from day +21 to day +34, and the lacrimal glands were harvested on day +35 post-BMT. (A) Representative images of MT staining of lacrimal glands harvested from syngeneic (Syn; upper panel) or Allo (lower panel) recipients on day +21 posttransplant. Scale bars, 50 µm. (B) Immunofluorescent images for HSP47 (red) with DAPI (blue) counterstaining on day +35. Arrows point to HSP47⁺ fibroblasts. Scale bars, 50 µm. (C) MT staining of lacrimal glands harvested from Allo mice given VA-lip Scr (Allo + Scr; upper panel) and Allo mice given VA-lip HSP47 (Allo + VA-lip HSP47; lower panel) on day +35 post-BMT. Scale bars, 50 µm. (D) The amount of collagen deposition in the lacrimal glands was evaluated before (Allo Day 21, n = 8) and after ocular instillation with VA-lip Scr (Allo + Scr Day 35, n = 8) or VA-lip HSP47 (Allo + VA-lip HSP47 Day 35, n = 7). Syn controls were evaluated on day +21 (n = 8). (E) Tear secretion was assessed before initiation of ocular instillation (Allo Day 21, n = 18) and after ocular instillation with VA-lip Scr (Allo + Scr Day 35, n = 8) or VA-lip HSP47 (Allo + VA-lip HSP47 Day 35, n = 10). Syn controls were evaluated on day +21 (n = 8). (D-E) Data from 2 similar experiments were combined. *P < .05; **P < .01; ***P < .005.